CAMBRIA-2 is a clinical trial aiming to stop breast cancer from coming back. It’s for people with early-stage oestrogen receptor-positive, HER2-negative breast cancer who face a medium to high risk of recurrence. The study is testing whether a treatment called a Selective Estrogen Receptor Degrader (SERD) can be more effective than standard hormone therapies like letrozole, anastrozole, exemestane, or tamoxifen. It will also give us important insights into side effects, safety, and effectiveness